Alexion's (NASDAQ: ALXN) third-quarter earnings beat estimates by 13 cents and sales of its popular drug Soliris were reported in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE